PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 28, 2026New England Journal of Medicine18 citations

Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer

View Full Paper
WPWungki ParkAKAnup Kumar KasiASAlexander I. Spira

Key Points

  • This research aims to evaluate the effectiveness of setidegrasib in patients with KRAS p.G12D-mutated non–small-cell lung cancer and pancreatic cancer.
  • Evaluated setidegrasib's antitumor activity
  • Monitored treatment discontinuation due to adverse events
  • Targeted patients with advanced KRAS p.G12D-mutated cancers
  • Setidegrasib was associated with significant antitumor activity
  • Low incidence of treatment discontinuation due to adverse events

Abstract

Setidegrasib was associated with antitumor activity and a low incidence of treatment discontinuation due to adverse events in patients with previously treated advanced KRAS p.G12D-mutated NSCLC or pancreatic ductal adenocarcinoma. (Funded by Astellas Pharma; ClinicalTrials.gov number, NCT05382559.).

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Park et al. (2026) studied this question.

synapsesocial.com/papers/69c770418bbfbc51511e06d2https://doi.org/10.1056/nejmoa2600752
Ask AI
Helpful
Bookmark
Share
View Full Paper